Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

392 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.
Sartor O, Goeckeler W, Bruland O. Sartor O, et al. Asian J Androl. 2011 Nov;13(6):783-4. doi: 10.1038/aja.2011.120. Epub 2011 Aug 22. Asian J Androl. 2011. PMID: 21857688 Free PMC article. No abstract available.
Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
Middleman MN, Lush RM, Sartor O, Reed E, Figg WD. Middleman MN, et al. Among authors: sartor o. Cancer Treat Rev. 1996 Mar;22(2):105-18. doi: 10.1016/s0305-7372(96)90030-4. Cancer Treat Rev. 1996. PMID: 8665563 Review. No abstract available.
Endpoints in prostate cancer clinical trials.
Sartor O. Sartor O. Urology. 2002 Sep;60(3 Suppl 1):101-7; discussion 107-8. doi: 10.1016/s0090-4295(02)01585-6. Urology. 2002. PMID: 12231062 Review.
Radioisotopic treatment of bone pain from metastatic prostate cancer.
Sartor O. Sartor O. Curr Oncol Rep. 2003 May;5(3):258-62. doi: 10.1007/s11912-003-0119-2. Curr Oncol Rep. 2003. PMID: 12667425 Review.
An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC. Sartor O, et al. Urology. 2003 Aug;62(2):319-23. doi: 10.1016/s0090-4295(03)00330-3. Urology. 2003. PMID: 12893343 Clinical Trial.
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P; Quadramet 424Sm10/11 Study Group. Sartor O, et al. Urology. 2004 May;63(5):940-5. doi: 10.1016/j.urology.2004.01.034. Urology. 2004. PMID: 15134985 Clinical Trial.
Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells.
Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY. Koochekpour S, et al. Among authors: sartor o. Asian J Androl. 2005 Jun;7(2):147-58. doi: 10.1111/j.1745-7262.2005.00037.x. Asian J Androl. 2005. PMID: 15897971
Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
Gandhok NK, Looney S, Koochekpour S, Sartor O. Gandhok NK, et al. Among authors: sartor o. Urol Oncol. 2005 May-Jun;23(3):163-7. doi: 10.1016/j.urolonc.2004.11.009. Urol Oncol. 2005. PMID: 15907715
Amplification and overexpression of prosaposin in prostate cancer.
Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Koochekpour S, et al. Among authors: sartor o. Genes Chromosomes Cancer. 2005 Dec;44(4):351-64. doi: 10.1002/gcc.20249. Genes Chromosomes Cancer. 2005. PMID: 16080200
392 results
Jump to page
Feedback